Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2828360 · 1 trial · 1 indication
The weekly mean of the 24-Hour APS was calculated from participants' daily entries for 24-hour average pain rating on an 11-point scale with scores from 0 (no pain) to 10 (worst possible pain). Data were recorded twice a day at approximately the same time each day, preferably first thing in the morning and in the afternoon.
| Arm | Type | Description |
|---|---|---|
| LY2828360 then Placebo | EXPERIMENTAL | 80 milligrams (mg) of LY2828360 daily by mouth for 4 weeks: placebo daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments. |
| Placebo then LY2828360 | EXPERIMENTAL | Placebo daily by mouth for 4 weeks: LY2828360 daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments. |
| Name | Type | Description |
|---|---|---|
| LY2828360 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Are male or female participants with osteoarthritis (OA), as determined by medical history and physical examination. Males and females with stable medical problems that, in the investigator's opinion, will not significantly alter the disposition of the drug, will not place the...
LY2828360 is an investigational small molecule being studied for the treatment of osteoarthritis of the knee. It was evaluated in a Phase 2 clinical trial for patients with osteoarthritic knee pain. The drug is not approved and remains in clinical development.
LY2828360 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company conducted a Phase 2 trial of the drug in patients with osteoarthritic knee pain.
LY2828360 is in Phase 2 clinical development. A Phase 2 trial of the drug for osteoarthritic knee pain has been completed. The drug is investigational and has not been approved by regulatory authorities.
LY2828360 has one completed clinical trial, registered as NCT01319929, titled "A Study of LY2828360 in Patients With Osteoarthritic Knee Pain." This Phase 2 study enrolled 39 participants in Denmark and was a randomized, double-blind, controlled trial.
LY2828360 is a small molecule, but its specific molecular target has not been disclosed in available information. Therefore, its mechanism of action is not described here.